Lenalidomide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100500

CAS#: 191732-72-6

Description: Lenalidomide, also known as CC-5013, is the thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. Lenalidomide is an approved drug.

Chemical Structure

img
Lenalidomide
CAS# 191732-72-6
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 100500
Name: Lenalidomide
CAS#: 191732-72-6
Chemical Formula: C13H13N3O3
Exact Mass: 259.10
Molecular Weight: 259.260
Elemental Analysis: C, 60.22; H, 5.05; N, 16.21; O, 18.51

Price and Availability

Size Price Availability Quantity
1g USD 150 Ready to ship
2g USD 250 Ready to ship
5g USD 550 Ready to ship
10g USD 950 Ready to ship
20g USD 1650 Ready to ship
500mg USD 90 Ready to ship
Bulk inquiry

Synonym: CC5013; CC-5013; CC 5013; IMiD1; Lenalidomide; US brand name: Revlimid.

IUPAC/Chemical Name: 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione

InChi Key: GOTYRUGSSMKFNF-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

SMILES Code: O=C(C(N(CC1=C2C=CC=C1N)C2=O)CC3)NC3=O

Appearance: White solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13nM.
In vitro activity: Natural killer T (NKT) cells are CD1d-restricted glycolipid reactive innate lymphocytes that play an important role in protection from pathogens and tumors. Antitumor properties of NKT cells are linked to their ability to secrete interferon-γ. NKT cells expanded in the presence of lenalidomide (LEN) had greater ability to secrete IFN-γ (Figure 2A). LEN also led to an increase in ligand-dependent induction of interferon-γ production by freshly isolated NKT cells in human peripheral blood mononuclear cells (PBMCs) (Figure 2D). Therefore, LEN leads to an increase in ligand-reactive interferon-γ secretion by human NKT cells in vitro. Reference: Blood. 2006;108(2):618-621. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895497/
In vivo activity: As shown in Fig. 5A, lenalidomide therapy achieved a significant mantle cell lymphoma (MCL) tumor regression (*, P < 0.05), when compared with vehicle groups. Tumors isolated from control and drug-treated MCL-bearing mice revealed a 40% reduction in tumor burden in the lenalidomide-receiving group (Fig. 5B). As exemplified in Fig. 5B and C, a remarkable decrease in the mitotic index, together with the activation of caspase-3 and the tightening of blood vessels, was observed in tumors from lenalidomide-receiving mice. Lenalidomide treatment induced a substantial decrease of cyclin D1 and p27KIP1, which was associated with the phosphorylation of the CDK inhibitor at threonine 198 (Fig. 5B and C). Taken together, these data confirm the in vitro observation that lenalidomide is able to impede the growth of MCL tumors with high cyclin D1 and p27KIP1 contents, its antitumor effect being related to the cytosolic redistribution p27KIP1, and subsequent apoptosis induction. Reference: Clin Cancer Res. 2014 Jan 15;20(2):393-403. https://clincancerres.aacrjournals.org/content/20/2/393.long

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 51.5 198.64
DMF 16.0 61.71
DMF:PBS (pH 7.2) (1:1) 0.5 1.93

Preparing Stock Solutions

The following data is based on the product molecular weight 259.260000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martínez A, Colomer D, Sola B, Roué G. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes. Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31. PMID: 24178620. 2. Jian W, Levitt JM, Lerner SP, Sonpavde G. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul;34(7):3383-9. PMID: 24982344.
In vitro protocol: 1. Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martínez A, Colomer D, Sola B, Roué G. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes. Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31. PMID: 24178620. 2. Jian W, Levitt JM, Lerner SP, Sonpavde G. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul;34(7):3383-9. PMID: 24982344.
In vivo protocol: 1. Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martínez A, Colomer D, Sola B, Roué G. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes. Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31. PMID: 24178620. 2. Jian W, Levitt JM, Lerner SP, Sonpavde G. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul;34(7):3383-9. PMID: 24982344.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nojkov B, Signori C, Konda A, Fontana RJ. Lenalidomide-associated hepatotoxicity--a case report and literature review. Anticancer Res. 2012 Sep;32(9):4117-9. Review. PubMed PMID: 22993370. 2: Kimby E. Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma. Curr Hematol Malig Rep. 2012 Sep;7(3):221-7. doi: 10.1007/s11899-012-0133-2. Review. PubMed PMID: 22895878. 3: Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A. Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1209-22. doi: 10.1517/17425255.2012.712685. Epub 2012 Aug 3. Review. PubMed PMID: 22862790. 4: Brower V. Lenalidomide maintenance for multiple myeloma. Lancet Oncol. 2012 Jun;13(6):e238. Review. PubMed PMID: 22833889. 5: Dawar R, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best Pract Res Clin Haematol. 2012 Jun;25(2):185-90. doi: 10.1016/j.beha.2012.04.005. Epub 2012 May 18. Review. PubMed PMID: 22687454. 6: Dimopoulos MA, Terpos E, Goldschmidt H, Alegre A, Mark T, Niesvizky R. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. Cancer Treat Rev. 2012 Dec;38(8):1012-9. doi: 10.1016/j.ctrv.2012.02.009. Epub 2012 May 18. Review. PubMed PMID: 22609463. 7: Segler A, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol. 2012 Jun;69(6):1393-406. doi: 10.1007/s00280-012-1874-2. Epub 2012 May 15. Review. PubMed PMID: 22584909. 8: Kunimasa K, Ueda T, Arita M, Maeda T, Hotta M, Ishida T. Drug-induced interstitial pneumonitis due to low-dose lenalidomide. Intern Med. 2012;51(9):1081-5. Epub 2012 Apr 29. Review. PubMed PMID: 22576392. 9: Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes. Curr Pharm Des. 2012;18(22):3198-203. Review. PubMed PMID: 22571699. 10: Barosi G, Merlini G, Billio A, Boccadoro M, Corradini P, Marchetti M, Massaia M, Tosi P, Palumbo A, Cavo M, Tura S. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Ann Hematol. 2012 Jun;91(6):875-88. doi: 10.1007/s00277-012-1445-y. Epub 2012 Apr 4. Review. PubMed PMID: 22476884.